Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Sharecare, Inc. SHCR

• Sharecare posted a narrower-than-expected first-quarter loss. "We are very pleased with our financial performance this quarter, which demonstrates our continued commitment to sustainable growth, cost optimization, and operational efficiency across our Enterprise, Provider, and Life Sciences channels," said Jeff Arnold, chairman and CEO of Sharecare. The company’s stock has a 52-week low of $1.24 .
• RSI Value: 29.62
• SHCR Price Action: Shares of Sharecare fell 3.7% to close at $1.30 on Wednesday.

Brainstorm Cell Therapeutics Inc. BCLI

• Brainstorm Cell Therapeutics recently announced pricing of $7.5 million registered direct offering. It has a 52-week low of $1.09.
• RSI Value: 25.90
• BCLI Price Action: Shares of Brainstorm Cell Therapeutics fell 3.6% to close at $1.63 on Wednesday.

Cosmos Health Inc. COSM

• Cosmos Health priced $5.25 million registered direct offering and concurrent private placement at combined price of $2.48. The company’s stock has a 52-week low of $0.0680.
• RSI Value: 22.33
• COSM Price Action: Shares of Cosmos Health fell 4.1% to close at $1.63 on Wednesday.

Beyond Air, Inc. XAIR

• Beyond Air reported worse-than-expected fourth-quarter EPS results. “We successfully completed our phase 1 limited commercial launch of LungFit PH in the United States signing multiple hospitals to contracts. We are pleased with the hard work and dedication demonstrated by our commercial team, and as planned, we have shifted into phase two where we are making significant progress in our efforts to expand the team and our geographic reach,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. The company’s 52-week low is $3.42.
• RSI Value: 28.87
• XAIR Price Action: Shares of Beyond Air fell 1.2% to close at $3.45 on Wednesday.

Protagonist Therapeutics, Inc. PTGX

• Protagonist Therapeutics recently reported acceptance of late-breaking abstract for oral presentation at 2023 European Hematology Association (EHA) Congress. The company has a 52-week low of $7.24.
• RSI Value: 28.25
• PTGX Price Action: Shares of Protagonist Therapeutics fell 1.2% to close at $19.13 on Wednesday.

Read More: Investor Sentiment Declines After Fed Raises Interest Rates By 0.25%